Alan Ashworth

University of California, San Francisco

Full Professor(heuristic)

PARP inhibition in cancer therapy · Oncology

h-index121

i10-index293

Publications1,039

Citations67,824

Grants

38 total · 6 active

NIH #5P50CA275741-02

Developmental Research Program (DRP)

Active

Amount: $82K
Period: 2024-09-02 → 2029-08-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #1P50CA275741-01A1

Developmental Research Program (DRP)

Active

Amount: $79K
Period: 2024-09-02 → 2029-08-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #5P30CA082103-26

Cancer Center Support Grant

Active

Amount: $8.2M
Period: 1999-08-05 → 2028-05-31
PIs: 1
Est. capacity / PI: ~9 students

Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.

All Grants

38 total · 6 active

NIH #5P50CA275741-02

Developmental Research Program (DRP)

Active

Amount: $82K
Period: 2024-09-02 → 2029-08-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #1P50CA275741-01A1

Developmental Research Program (DRP)

Active

Amount: $79K
Period: 2024-09-02 → 2029-08-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #5P30CA082103-26

Cancer Center Support Grant

Active

Amount: $8.2M
Period: 1999-08-05 → 2028-05-31
PIs: 1
Est. capacity / PI: ~9 students

NIH #5P30CA082103-25

Cancer Center Support Grant

Active

Amount: $8.1M
Period: 1999-08-05 → 2028-05-31
PIs: 1
Est. capacity / PI: ~8 students

NIH #3P30CA082103-24S1

Cancer Center Support Grant

Active

Amount: $296K
Period: 1999-08-05 → 2028-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #2P30CA082103-24

Cancer Center Support Grant

Active

Amount: $8.1M
Period: 1999-08-05 → 2028-05-31
PIs: 1
Est. capacity / PI: ~8 students

NIH #5R01CA230516-05

DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications

Amount: $510K
Period: 2018-09-01 → 2023-08-31
PIs: 2
Est. capacity / PI: ~0 students

NIH #5R01CA230516-04

DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications

Amount: $529K
Period: 2018-09-01 → 2023-08-31
PIs: 2
Est. capacity / PI: ~0 students

NIH #5R01CA230516-03

DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications

Amount: $538K
Period: 2018-09-01 → 2023-08-31
PIs: 2
Est. capacity / PI: ~0 students

NIH #3R01CA230516-02S1

DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications

Amount: $55K
Period: 2018-09-01 → 2023-08-31
PIs: 2
Est. capacity / PI: ~0 students

NIH #5R01CA230516-02

DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications

Amount: $527K
Period: 2018-09-01 → 2023-08-31
PIs: 2
Est. capacity / PI: ~0 students

NIH #5P30CA082103-23

Cancer Center Support Grant

Amount: $8.0M
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-23S3

Cancer Center Support Grant

Amount: $15K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-23S1

Cancer Center Support Grant

Amount: $115K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-23S2

Cancer Center Support Grant

Amount: $26K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-23S4

Enhancing Sexual Orientation and Gender Identity (SOGI) Data Collection at the HDFCCC

Amount: $150K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #5P30CA082103-22

Cancer Center Support Grant

Amount: $8.0M
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-22S1

Cancer Center Support Grant

Amount: $128K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-22S2

Cancer Center Support Grant

Amount: $130K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-22S3

Project HOPE: The Pediatric/AYA Omics Project

Amount: $340K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-22S4

Cancer Clinical Investigator Team Leadership Award

Amount: $115K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21S2

Cancer Center Support Grant

Amount: $42K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21SA

Cancer Center Support Grant

Amount: $200K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21S5

Cancer Center Support Grant

Amount: $111K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21S4

Cancer Center Support Grant

Amount: $96K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21S1

Cancer Center Support Grant

Amount: $44K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21S3

Cancer Center Support Grant

Amount: $115K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21S6

Cancer Center Support Grant

Amount: $300K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21S7

Cancer Center Support Grant

Amount: $100K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-21S9

Cancer Center Support Grant

Amount: $500K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-20S2

Cancer Center Support Grant

Amount: $300K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-20S1

Cancer Center Support Grant

Amount: $250K
Period: 1999-08-05 → 2023-05-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #3P30CA082103-22S5

Patient Navigator Education and Training Strategies to Support Cancer Survivors in Tanzania

Amount: $178K
Period: 2022-01-01 → 2022-12-31
PIs: 1
Est. capacity / PI: ~0 students

NIH #5U54CA209891-05

Mapping the Pharmacogenetic Landscape for Precision Medicine

Amount: $501K
Period: 2017-05-11 → 2022-04-30
PIs: 1
Est. capacity / PI: ~0 students

NIH #5U54CA209891-04

Mapping the Pharmacogenetic Landscape for Precision Medicine

Amount: $540K
Period: — → —
PIs: 1
Est. capacity / PI: ~9 students

NIH #5P30CA082103-21

Developmental Funds

Amount: $301K
Period: — → —
PIs: 1
Est. capacity / PI: ~5 students

NIH #5U54CA209891-03

Mapping the Pharmacogenetic Landscape for Precision Medicine

Amount: $563K
Period: — → —
PIs: 1
Est. capacity / PI: ~9 students

NIH #5P30CA082103-20

Leadership, Planning, and Evaluation

Amount: $883K
Period: — → —
PIs: 1
Est. capacity / PI: ~14 students

Lab Funding Health

Find elsewhere

Institution / lab homepage Search on ResearchGate

In-Field Influence

0.0014

PageRank within Oncology co-authorship network

Explore collaboration map

Admission Signals

New paper: Supplementary Fig. S14 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy2026-06-17
New NIH award: $82K — Developmental Research Program (DRP)2024-09-02
New NIH award: $79K — Developmental Research Program (DRP)2024-09-02
New NIH award: $8,230K — Cancer Center Support Grant1999-08-05
New NIH award: $8,130K — Cancer Center Support Grant1999-08-05
New NIH award: $296K — Cancer Center Support Grant1999-08-05
New NIH award: $8,130K — Cancer Center Support Grant1999-08-05

Data Freshness

Publications as of 2026-07-01
Grants as of 2026-06-30

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

ORCID: 0000-0003-1446-7878

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 175

Supplementary Fig. S14 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Data from Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies
2026-06-17
Supplementary Figure 1 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models
2026-06-17
Supplementary Fig. S15 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Figure 6 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models
2026-06-17
Supplementary Figure 3 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models
2026-06-17
Supplementary Fig. S6 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S7 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S12 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S3 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S11 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S10 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S5 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Figure 5 from PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models
2026-06-17
Supplementary Fig. S13 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S2 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S4 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S9 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S1 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17
Supplementary Fig. S7 from Perivascular NOTCH3+ Stem Cells Drive Meningioma Tumorigenesis and Resistance to Radiotherapy
2026-06-17

Open author page on OpenAlex →